Welcome to the Pacific Hepatitis C Network (PHCN)‘s Hepatitis C News in Review Newsletter. This is where we review all of the major current issues and events around hepatitis C and hep C treatments. It is an email that includes links to our recent blog posts—including links to blog posts about the BC Ministry of Health announcing that they are now covering additional hepatitis C treatments.
‘No One Left Behind!’
Pacific Hepatitis C Network (PHCN) is very happy to learn that effective March 21, an extensive list of hepatitis C treatments will be available through BC PharmaCare – at far better prices than they previously had been. The high cost of hepatitis C treatment has effectively restricted the numbers of people living with hepatitis C who could access treatment…
Agreements between the pCPA and Gilead Sciences Canada, Merck Canada, and Bristol-Myers Squibb Canada were reached to provide several hepatitis C drugs at an improved cost:
- Daklinza (daclatasvir) – new
- Epclusa (sofosbuvir/velpatasvir) – new
- Harvoni (ledipasvir/sofosbuvir)
- Sovaldi (sofosbuvir)
- Sunvepra (asunaprevir) – new
- Zepatier (elbasvir/grazoprevir) – new
PharmaCare announced that starting in 2018-19, they will provide coverage for any British Columbian living with chronic hepatitis C, regardless of the type or severity of their disease.
Effective February 28, 2017, the following hepatitis C drug products will be funded under the Ontario Drug Benefit (ODB) Program for eligible ODB recipients for the treatment of hepatitis C.
• Harvoni (ledipasvir/sofosbuvir)
• Sovaldi (sofosbuvir)
• Epclusa (sofosbuvir/velpatasvir)
• Zepatier (elbasvir/grazoprevir)
• Daklinza (daclatasvir)
• Sunvepra (asunaprevir)
• Ibavyr (ribavirin)
The Conference on Retroviruses and Opportunistic Infections (CROI), an annual preeminent HIV research meeting, was held in Seattle, Washington, February 13-16 this year. CROI gathers scientists researching epidemiology and biology of human retroviruses and associated diseases to discuss their findings. The following blog posts highlight HIV/HCV information that was at the conference.
- CROI 2017 Hep C Highlights Part I
- CROI 2017 Hep C Highlights Part II
- CROI 2017 by Lucinda K. Porter, RN
REFLECTIONS BY PHCN’S PRESIDENT DARYL LUSTER
- Reflections on the Public Health Agency of Canada (PHAC)’s Sexually Transmitted and Blood Borne Infection (STBBI) Stakeholders Meeting in Ottawa, February 23-24 2017
- Thoughts by Daryl Luster: Recent Writings by a Hep C Advocate